Scopus BioPharma Inc. announced the appointment of Raphael (Rafi) Hofstein to its Board of Directors (Board). Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been instrumental in the founding and/or leadership of over 60 biopharmaceutical and biotechnology companies.

These companies include Fibrocor Therapeutics, a precision medicine company; BioLineRx; and Encycle Therapeutics. Dr. Hofstein is Chairman of Fibrocor, which has strategic partnerships with Evotec SE and Galapagos NV. Dr. Hofstein has been a director of BioLineRx since its inception.

Encycle was acquired by Zealand Pharma A/S in 2019. Dr. Hofstein has also played key leadership roles in establishing industry partnerships and strategic alliances with leading global biopharmaceutical, biotechnology and pharmaceutical companies, including Amgen, Baxter, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer and Takeda. Dr. Hofstein fills a vacancy on the Board created by the voluntary resignations of directors who joined the Board as a result of the contested election relating to the 2021 Annual Meeting of Stockholders.

The results of the contested election are being challenged in an action pursuant to Section 225 of Delaware's General Corporation Law in the Delaware Court of Chancery.